PRODUCT ANALYSIS: THE DEVICE REMAINS IMPLANTED, THEREFORE NO PRODUCT ANALYSIS CAN BE PERFORMED. CONCLUSION: WITHOUT RETURN OF THE PRODUCT, NO DEFINITIVE CONCLUSIONS COULD BE DRAWN REGARDING THE CLINICAL OBSERVATION. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
D
Patient 1
MEDTRONIC RECEIVED INFORMATION THAT APPROXIMATELY EIGHT YEARS AND TEN MONTHS AFTER THE IMPLANT OF THIS TRANSCATHETER BIOPROSTHETIC PULMONARY VALVE, THE VALVE WAS REPLACED VALVE-IN-VALVE DUE TO SEVERE PULMONARY INSUFFICIENCY AND RIGHT VENTRICLE DILATION. NO ADDITIONAL ADVERSE PATIENT EFFECTS WERE REPORTED.